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OBJECTIVES We administered pilsicainide chloride, a class Ic pure sodium channel blocker, to patients
with Brugada syndrome (BS) and evaluated the occurrence of ventricular arrhythmia (VA)
and T-wave alternans (TWA).
BACKGROUND Ventricular arrhythmia and TWA are sometimes induced by a sodium channel blocker
challenge test in BS patients, but the significance of the induced VA and TWA is not
known.
METHODS Pilsicainide was administered to 65 patients with BS (10 symptomatic and 55 asymptomatic
patients), and the occurrence of VA, TWA, and change of electrocardiogram were evaluated.
Electrophysiologic study was performed in 57 patients, and the induction of VA by
programmed electrical stimulation (PES) was evaluated.
RESULTS Ventricular arrhythmia was not induced by administration of pilsicainide in 55 patients
(no-VA group). Administration of pilsicainide-induced VA in 10 patients (Pil-VA group)
and polymorphic ventricular tachycardia in four patients. Pilsicainide-induced VA in 60% of
the symptomatic patients but in only 7% of asymptomatic patients (p 0.01). ST level, QTc,
and indexes of cardiac conduction in the Pil-VA group were not different from those in the
no-VA group. Ventricular fibrillation was induced by PES in 67% of the patients in the
Pil-VA group and in 33% of the patients in the no-VA group. In six cases, macroscopic TWA
occurred in association with pilsicainide-induced VA, but TWA occurred in only one patient
without pilsicainide-induced arrhythmia.
CONCLUSIONS Administration of a sodium channel blocker results in induction of not only ST-elevation but
also VA and TWA in patients with BS. (J Am Coll Cardiol 2003;42:1624–31) © 2003 by
the American College of Cardiology Foundation
In 1992, Brugada et al. (1) reported eight patients with right
bundle branch block and persistent ST-segment elevation in
right precordial leads. These patients experienced syncope
episodes, and polymorphic ventricular tachycardia (VT) or
ventricular fibrillation (VF) was induced by programmed
electrical stimulation (PES). Brugada-type electrocardio-
gram (ECG) was unmasked and augmented by antiarrhyth-
mic drug (class Ia or Ic) challenge test (2–8). Administra-
tion of a sodium channel blocker induces change in cardiac
ion channel function and results in morphologic change in
action potential and phase 2 reentry at the right ventricular
free wall in patients with Brugada syndrome (9–12). If the
antiarrhythmic drug causes phase 2 reentry, ventricular
arrhythmia (VA) is expected to occur after administration of
a class Ia or Ic antiarrhythmic drug. In this study, we,
therefore, examined the effects of administration of an
antiarrhythmic drug in patients with Brugada-type ECG.
We used pilsicainide chloride, which is classified as a class Ic
antiarrhythmic drug and has been shown to have a pure
sodium channel-blocking effect (13,14).
METHODS
Patients. The subjects of this study were 64 male patients
and a female patient with Brugada-type ECG (10 symp-
tomatic and 55 asymptomatic patients), and the mean age of
the subjects was 47  12 years. Brugada-type ECG was
defined as J wave (higher than 0.2 mV) and ST-segment
elevation (higher than 0.1 mV) (15). Symptomatic patients
had recurrent syncope episodes of unknown origin (three
patients) or had been resuscitated from cardiac arrest or VF
(seven patients). All of the subjects had right bundle branch
block with spontaneous ST-segment elevation without drug
provocation, and patients who showed Brugada-type ECG
only after the class I antiarrhythmic challenge test were not
included in this study. There were no patients from the
same family. Various cardiac imaging techniques, including
echocardiography and right ventriculography, were per-
formed in all patients, but no abnormalities were found. The
risks of the electrophysiologic study and drug test were
explained to each patient, and written informed consent was
obtained from all patients.
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Electrophysiologic study. The electrophysiologic study
was performed in 57 patients (10 symptomatic and 47
asymptomatic patients), and induction of VA was at-
tempted without the use of any antiarrhythmic drugs.
The criterion for induction of VA was induction of
sustained polymorphic VT or VF by PES from the right
ventricular apex, right ventricular outflow tract, or left
ventricle. The protocol of ventricular stimuli included up
to three extrastimuli (two basic cycle lengths of 600 and
400 ms) and rapid ventricular pacing, with the coupling
interval of the extrastimuli not being 180 ms and the
ventricular rate of rapid burst pacing not exceeding 270
beats/min. The electrophysiologic study was performed
as reported previously (16).
Pharmacologic challenge with a sodium channel blocker.
Pilsicainide chloride was administered to all patients, orally
at a dose of 150 mg in 18 patients and intravenously at a
dose of 1 mg/kg over a 6-min period in 47 patients. ST level
was measured at the J points in leads V1 and V2, and the
difference between the ST levels before and after adminis-
tration of pilsicainide (augmentation of ST level) was
calculated. PQ interval, QRS interval, QTc interval, His-
ventricle (HV) interval, and depth of S wave in leads II and
V5 were measured before and after administration of pilsic-
ainide. Occurrence of VA and macroscopic T-wave alter-
nans after administration of pilsicainide were also evaluated.
The VA during the pilsicainide test included frequent
occurrence of ventricular premature beat (PVC) (1 beats/
min) and polymorphic VT (at least 3 beats).
Statistical analysis. Quantitative values are expressed as
means  1 SD. Statistical significance in differences was
analyzed by Mann-Whitney U test for unpaired values and
Student t test for paired values (the values before and after
administration of pilsicainide). A value of p  0.05 was
considered statistically significant.
Table 1. Electrocardiographic Changes Before and After Administration of Pilsicainide
Group
All Patients
(n  65)
Pil-VA ()
(n  10)
Pil-VA ()
(n  55) p Value*
ST level
Lead V1
Before pilsicainide (mV) 0.13  0.07 0.14  0.08 0.13  0.07 0.90
After pilsicainide (mV) 0.26  0.16 0.30  0.15 0.25  0.16 0.21
Lead V2
Before pilsicainide (mV) 0.26  0.12 0.28  0.15 0.26  0.12 0.95
After pilsicainide (mV) 0.61  0.33 0.61  0.22 0.60  0.34 0.52
Augmentation of V1 ST level (mV) 0.13  0.11 0.16  0.08 0.12  0.12 0.17
Augmentation of V2 ST level (mV) 0.34  0.26 0.33  0.13 0.34  0.27 0.75
PQ interval
Before pilsicainide (s) 0.17  0.02 0.18  0.03 0.17  0.02 0.51
After pilsicainide (s) 0.22  0.03 0.22  0.03 0.22  0.03 0.84
QRS interval
Before pilsicainide (s) 0.09  0.01 0.10  0.02 0.09  0.01 0.08
After pilsicainide (s) 0.11  0.02 0.13  0.03 0.11  0.01 0.04
QTc interval
Before pilsicainide (s) 0.40  0.04 0.41  0.05 0.40  0.03 0.41
After pilsicainide (s) 0.43  0.03 0.45  0.05 0.43  0.03 0.22
HV interval
Before pilsicainide (ms) 38  8 39  5 37  9 0.68
After pilsicainide (ms) 56  8 57  8 56  9 0.51
Left axis deviation
Before pilsicainide 14/65 (22%) 3/10 (30%) 11/55 (20%) 0.48
After pilsicainide 25/65 (38%) 3/10 (30%) 22/55 (40%) 0.55
Depth of S-wave
Lead II
Before pilsicainide (mV) 0.28  0.22 0.21  0.28 0.29  0.21 0.09
After pilsicainide (mV) 0.45  0.26 0.36  0.36 0.47  0.24 0.14
Lead V5
Before pilsicainide (mV) 0.44  0.31 0.40  0.32 0.44  0.31 0.48
After pilsicainide (mV) 0.75  0.38 0.65  0.39 0.77  0.38 0.26
Data are presented as the mean value  SD. *p value for difference between patients of Pil-VA () and Pil-VA ().
Pil VA ()  patients with pilsicainide-induced ventricular arrhythmia; Pil VA ()  patients without pilsicainide-induced
ventricular arrhythmia.
Abbreviations and Acronyms
HV  His-ventricle
PES  programmed electrical stimulation
PVC  premature ventricular contraction
TWA  T-wave alternans
VA  ventricular arrhythmia
VF  ventricular fibrillation
VT  ventricular tachycardia
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RESULTS
ECG change after administration of pilsicainide. Table
1 shows ECG changes induced by administration of pilsic-
ainide. ST levels in leads V1 and V2, PQ interval, QRS
interval, QTc interval, and HV interval were augmented
after the pilsicainide test compared with those values before
the pilsicainide test (p  0.01). The percentage of patients
with left axis deviation (QRS axis 30 degrees) and the
depth of S wave in leads II and V5 increased after admin-
istration of pilsicainide (p  0.01).
VA induced by pilsicainide administration. No VA was
observed before administration of pilsicainide in any of the
patients. Pilsicainide-induced VA in 10 (15%) of the 65
patients (Figs. 1 and 2, Table 2). Pilsicainide induced VA in
60% of the symptomatic patients (six patients) but in only
7% of the asymptomatic patients (four patients) (p  0.01).
Polymorphic VT occurred after administration of pilsicain-
ide in four patients (three symptomatic patients and one
asymptomatic patient), and frequent PVC occurred in other
patients. In two symptomatic patients, 0.1 g/min of
isoproterenol infusion was started because of frequent PVC
(case 7) and incessant polymorphic VT (case 9). Ventricular
arrhythmia was diminished after starting infusion of isopro-
terenol in both cases, but VF re-occurred 1 h after cessation
of isoproterenol infusion (7 h after administration of pilsic-
ainide) in case 9 (Fig. 3).
The VA occurred within 15 min (mean time: 5.8  3.1
min) after intravenous administration of pilsicainide, but
late occurrence of VA (4 h and 7 h after intravenous
administration) was observed in two cases (cases 7 and 9)
(Table 2).
ST levels in lead V1 and V2, augmentation of ST level,
PQ interval, QTc interval, HV interval, and depth of S wave
before and after administration of pilsicainide did not
influence the occurrence of pilsicainide-induced VA (Table
1). In patients with pilsicainide-induced VA, QRS interval
after administration of pilsicainide was slightly longer than
that in patients without pilsicainide-induced arrhythmia.
Ventricular fibrillation was induced by PES in 34% of the
patients (22 patients). Programmed electrical stimulation
induced VF in 67% of the patients with pilsicainide-induced
arrhythmia (six patients) but in only 33% of the patients
without pilsicainide-induced arrhythmia (16 patients).
Characteristics of premature ventricular contractions.
There were two types of QRS morphology of pilsicainide-
induced PVC. Eight of the 10 patients with PVC showed
QRS morphology of the left bundle branch block with
inferior axis (Fig. 1a), and the same PVC preceded poly-
morphic VT in two patients (Fig. 2). In two patients, PVC
showed QRS morphology of the left bundle branch block
with superior axis, and the same PVC induced polymorphic
VT (Fig. 1b). The coupling interval of pilsicainide-induced
VA was 0.41  0.04 s.
T-wave alternans (TWA) induced by pilsicainide admin-
istration. Administration of pilsicainide induced manifest
TWA in right precordial leads in 7 (11%) of the 65 patients.
T-wave alternans occurred in 6 (60%) of 10 patients with
pilsicainide-induced VA but in only one (2%) of the 55
patients without pilsicainide-induced arrhythmia (Figs. 4
and 5). T-wave alternans did not occur before administra-
tion of pilsicainide. ST levels in leads V1 and V2, augmen-
tation of ST level, PQ interval, QRS interval, QTc interval,
HV interval, and depth of S wave before and after admin-
istration of pilsicainide did not influence the occurrence of
macroscopic TWA.
Figure 1. Pilsicainide-induced ventricular arrhythmia. (a) shows electro-
cardiogram (ECG) after administration of pilsicainide in case 3. A couplet
of premature ventricular contraction (PVC) occurred, and QRS morphol-
ogy of the PVC was left bundle branch block with inferior axis. (b) shows
ECG after administration of pilsicainide in case 5. A triplet of PVC
occurred, and QRS morphology of PVC was left bundle branch block with
superior axis.
Figure 2. Pilsicainide-induced ventricular tachycardia in case 9. (a) shows
control electrocardiogram before administration of pilsicainide. (b) shows
nonsustained polymorphic ventricular tachycardia immediately after ad-
ministration of pilsicainide.
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DISCUSSION
Brugada et al. (3) reported that sodium channel blocking
agents unmasked the typical Brugada-type ECG pattern,
that is, right bundle branch block with ST-segment eleva-
tion in right precordial leads, and enabled identification of
patients at risk for sudden death. Moreover, some studies
have shown the efficacy of a sodium channel blocker for
diagnosis and determination of the characteristic ECG
changes in patients with Brugada syndrome (2–8,17–20). It
has been suggested that genetic sodium channel dysfunction
can explain the ST-elevation and the occurrence of VA,
which are exaggerated by administration of the sodium
channel blocker (9–12). It was, therefore, thought that
provocation and exaggeration of the Brugada-type ECG
pattern by administration of a sodium channel blocker
would enable risk stratification of patients. However, later
studies showed that Brugada-type ECG pattern that was
provoked only by a sodium channel blocker was not a
predictor of the prognosis of patients with Brugada syn-
drome (21,22). It has recently been reported that adminis-
tration of a sodium channel blocker resulted in not only
enhancement of ST-segment elevation but also other char-
acteristic ECG changes in patients with Brugada syndrome.
Pilsicainide chloride, which is classified as a class Ic antiar-
rhythmic drug and has been shown to have a pure sodium
channel-blocking effect (13,14), was used for evaluation of
patients with Brugada-type ECG in this study.
Induction of VA by administration of a sodium channel
blocker. Some studies have shown that administration of a
sodium channel blocker resulted in induction of ST-
elevation and VA, but detailed evaluation was not carried
out in these studies. Occurrence of VF in some patients with
Brugada syndrome after administration of a sodium channel
blocker has been reported recently (19,21,23,24), and Wilde
et al. (17) recommended that drug tests should be discon-
tinued if PVC is evident. A total of 15% of patients in the
present study showed VA after administration of the so-
dium channel blocker, and the occurrence of arrhythmia was
not associated with indexes of repolarization (level of
ST-segment and QTc interval) or with indexes of depolar-
ization (PQ interval, HV interval, and depth of S wave)
before and after administration of pilsicainide or results of
electrophysiologic study. QRS interval after administration
of pilsicainide only showed slight prolongation in patients
with pilsicainide-induced arrhythmia. Four patients in the
present study showed nonsustained VT after administration
of the sodium channel blocker. Although VT was self-
limiting in three patients, a cluster of rapid VT events
occurred incessantly, and implantable cardioverter defibril-
lator discharged shocks in one patient. Careful monitoring
should be performed after administration of a sodium
channel blocker, because VA occurred even several hours
after injection of the drug in this study. Because VA after
administration of the sodium channel blocker occurred in
half of the symptomatic patients but in only a few of the
asymptomatic patients, these arrhythmias might be an
indicator of high-risk patients.
The VA after administration of the sodium channel
blocker might have originated in the right ventricular
outflow tract in most cases in this study, because the QRS
morphology of arrhythmia showed left bundle branch block
with inferior axis. Some studies have shown that VF was
frequently induced at the right ventricular outflow tract by
PES and that spontaneous PVC frequently originated in the
right ventricular outflow tract, which might be a critical site
in Brugada syndrome (16,25–27). Although the term
“proarrhythmia” should be defined as the occurrence of
various arrhythmias after administration of antiarrhythmic
drugs, it is suggesting that the occurrence of VAs after
administration of a sodium channel blocker is specific to
patients with Brugada-type ECG, because the incidence of
pilsicanide-induced VA was high and it was associated with
typical ECG changes in patients with Brugada-type ECG
in the present study.
Induction of macroscopic TWA by a sodium channel
blocker. As another ECG change after administration of
pilsicainide, some patients showed TWA in right precordial
leads. Manifest TWA has been reported to occur in patients
with Brugada syndrome in various situations such as after
Table 2. Pilsicainide-Induced VA in Patients With Brugada-Type ECG
Case Age Gender Symptom
ST Morphology
Without Pilsicainide EPS
Administration
of Pilsicainide
Pilsicainide
Induced VA
Onset of
VA TWA
1 50 M asymptomatic coved not induced IV PVC 11 min 
2 27 M asymptomatic coved VF IV PVC 5 min 
3 41 M asymptomatic saddle back VF IV P-VT 9 min 
4 75 M asymptomatic coved NA IV PVC 5 min 
5 41 M VF saddle back VF IV P-VT 6 min 
6 42 M VF saddle back VF IV PVC 4 min 
7 55 M VF coved VF IV PVC 4 h 
8 56 M VF coved not induced PO PVC 60 min 
9 55 M VF coved VF IV P-VT 1 min, 7 h 
10 41 M syncope coved not induced IV P-VT 5 min 
EPS  electrophysiological study; IV  intravenously; M  male; NA  not assessed; PO  per oral; PVC  premature ventricular contraction; P-VT  polymorphic
ventricular tachycardia; TWA  T-wave alternans; VA  ventricular arrhythmia; VF  history of ventricular fibrillation.
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Figure 3. Intracardiac electrogram during pilsicainide-induced ventricular tachycardia by an implantable cardioverter defibrillator in case 9. (a) Incessant polymorphic ventricular tachycardia occurred
immediately after intravenous administration of pilsicainide. (b) Ventricular fibrillation occurred 7 h after injection of pilsicainide, and it was terminated by implantable cardioverter defibrillator therapy.
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administration of a sodium channel blocker, during atrial
pacing, and during febrile illness (23,24,28–30). It is
thought that TWA shows instability of repolarization (31).
Both depolarization and repolarization abnormalities might
influence the pathogenesis of Brugada syndrome (10,25,32),
and electrical instability of the repolarization phase would
cause VA. Ikeda et al. (26) reported microvolt TWA
alternans that was induced by exercise in 16% of Brugada
patients but was not a predictor of patients at high risk. In
their patients, TWA was induced by exercise, but exercise
tests frequently cause attenuation of ST-segment levels in
patients with Brugada syndrome (33); thus, the mechanism
of development of microvolt-TWA and that of develop-
ment of TWA induced by a sodium channel blocker should
be different (26). Because TWA induced by a sodium
channel blocker occurred together with exaggeration of ST
level and VA, it is thought that TWA results from the same
pathologic depolarization and repolarization abnormalities
in patients with Brugada syndrome.
Clinical implication. Because the occurrence of VA and
TWA after administration of a sodium channel blocker are
phenomena-specific to symptomatic patients with Brugada
syndrome, risk stratification of the Brugada syndrome could
be performed by these phenomena. Sodium channel block-
ers have frequently been used for treatment of atrial fibril-
lation, and some patients have shown Brugada-type ECG
after administration of a sodium channel blocker. Clinicians
should pay attention to not only ST-elevation but also to the
Figure 4. Occurrence of T-wave alternans after administration of pilsicainide in case 4. (a) shows control electrocardiogram before administration of
pilsicainide. (b) shows premature ventricular contraction (PVC) and manifest T-wave alternans in right precordial leads after administration of pilsicainide:
PVC occurred on a deep inverted T wave. Arrows  larger inverted T wave in lead V2.
Figure 5. Occurrence of T-wave alternans after administration of pilsicainide in case 9. (a) shows control electrocardiogram before administration of
pilsicainide. (b) shows small but manifest T-wave alternans after administration of pilsicainide. Arrows  T waves of larger amplitude.
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occurrence of TWA and VA because patients in whom
these phenomena occur have a concealed form of Brugada
syndrome, and lethal VA will occur in some patients after
administration of a sodium channel blocker.
Study limitations. We were not able to detect genetic
abnormalities, and responses to sodium channel blockade
and abnormal late potentials might depend on the genotype.
However, determination of genotype in Brugada syndrome
is difficult, because it has been reported that prevalence of
mutations in the cardiac sodium channel was only 15% (6).
We used both intravenous administration and per oral
administration of pilsicainide, but we did not compare the
serum drug concentrations after administration by these two
methods. ST level and occurrence of VA after administra-
tion of pilsicainide might be influenced by the method of
administration. However, considering the half-lives of the
drugs and the risks of drug tests for patients with Brugada
syndrome, intravenous injection is superior to per oral
administration.
Conclusions. Administration of pilsicainide induced VA
in 15% of the patients and manifest TWA in 11% of the
patients. The occurrence of VA after administration of
pilsicainide was not associated with the indexes of depolar-
ization and repolarization. T-wave alternans occurred in
association with VA. The occurrence of VA and TWA after
administration of a sodium channel blocker are phenomena-
specific to Brugada syndrome.
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